Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で37.12%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 22.47Mに達しています。
適正水準
同社の最新のPEは-4.61で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は161.77M株で、前四半期比で15.79%増加しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.18です。